NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

Key facts

Sponsor

Stephen G. Kaler, MD

Principal Investigator

Stephen G Kaler, MD

Vagelos College of Physicians & Surgeons, Columbia University, New York, NY

Intervention

Droxidopa(drug)

Enrollment

3 enrolled

Eligibility

18-50 years · All sexes

Timeline

2021 – 2024

Study locations (1)

• Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Menkes disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07398508
  Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease.
  Stephen G. Kaler
• ACTIVE NOT RECRUITINGNANCT04337684
  Long Term Follow-up on Menkes Disease Patients
  Sentynl Therapeutics, Inc.

See all trials for Menkes disease →